Skip to content

Ambrisentan

Endothelin Receptor Antagonist — CARDIOVASCULAR SYSTEM

Also known as: letairis, LU 208075, LU208075, volibris

OfpEMA approvedFDA approvedPMDA approvedOrphan designationATC C02KX02ATC C02KX52

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ambrisentan is an ofp drug in the Endothelin Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Endothelin Receptor Antagonists. DrugCentral lists 2 molecular targets, including EDNRA and EDNRB. Recorded indications include Pulmonary arterial hypertension.

  • Approval status: ofp (first approved 2007 by the FDA).
  • Drug class: Endothelin Receptor Antagonist.
  • Mechanism of action: Endothelin Receptor Antagonists.
  • Molecular targets: EDNRA and EDNRB (2 listed in DrugCentral).
  • Indications: Pulmonary arterial hypertension.
  • ATC code: C02KX02 (Antihypertensives for pulmonary arterial hypertension).
  • Molecular formula: C22H22N2O4; molecular weight 378.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Pulmonary arterial hypertension

Contraindications (9)

  • Anemia
  • Body fluid retention
  • Breastfeeding (mother)
  • Chronic heart failure
  • Edema
  • Liver function tests abnormal
  • Oligozoospermia
  • Pregnancy, function
  • Pulmonary veno-occlusive disease

Mechanism & targets

Mechanism of action (MoA)Endothelin Receptor Antagonists
Established pharmacologic classEndothelin Receptor Antagonist

Molecular targets (2)

TargetGeneActionActivity
Endothelin-1 receptorEDNRAantagonistKi 9.65
Endothelin B receptorEDNRBantagonistKi 6.98

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2021-03-23PMDA—GlaxoSmithKline K.K.Yes
2019-06-20EMA—MYLAN SAS
2007-06-15FDA—GILEADYes

ATC classification

ATC codeTherapeutic hierarchy
C02KX02CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension
C02KX52CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Dyspnoea6403.3
Fluid retention3816.7
Death3327.4
Headache2639.3
Pain in jaw2595.8
Nasal congestion2476.9
Pulmonary arterial hypertension2088.8
Right ventricular failure1789.9
Hypervolaemia1627.7
Pulmonary hypertension1594.9
Flushing1463.0
Oedema1431.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ambrisentan is on its molecule page.

Molecular formulaC22H22N2O4
Molecular weight378.43 g/mol
CAS number177036-94-1
InChIKeyOUJTZYPIHDYQMC-LJQANCHMSA-N
PubChem CID6918493
COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ambrisentan used for?

DrugCentral lists the following indications for Ambrisentan: Pulmonary arterial hypertension.

How does Ambrisentan work?

Ambrisentan is classified as Endothelin Receptor Antagonists; its molecular targets in DrugCentral include EDNRA (antagonist) and EDNRB (antagonist).

When was Ambrisentan first approved?

Ambrisentan was first approved by the FDA in 2007.

What drug class does Ambrisentan belong to?

Ambrisentan is in the Endothelin Receptor Antagonist class.

What is the chemical formula of Ambrisentan?

Ambrisentan has the molecular formula C22H22N2O4 and a molecular weight of 378.43 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2007-06-15
AgencyFDA
Targets2
Indications1
FormulaC22H22N2O4
DrugCentral ID4337
Interactive profile